Corteva, Milestone, Ondas Price Targets, November 16 2026

Corteva

Corteva sells crop protection products, such as herbicides, insecticides and fungicides, to farmers around the world. It kept that business after spinning off its seed unit as Vylor. The company reported third-quarter results on Wednesday, November 11. Revenue, reported as net sales, came to $1.59 billion, 10.2% below the $1.77 billion consensus. Adjusted operating earnings were $0.06 a share, 40% below the $0.10 expected.

What Drove Corteva’s Quarter

Net sales shrank 9%. Volume accounted for 2 points of that and pricing for 7. Latin America sales were $570 million, against $791 million a year earlier. Volume there shrank 24% and pricing shrank 7%. Chief executive Luke Kissam said “Brazil was materially weaker than anticipated.” The company’s outlook section points to tight farmer liquidity, high financing costs and pricing pressure.

North America sales grew to $574 million from $537 million, and volume grew 19%. The company said lower U.S. pricing on acetochlor, a corn herbicide, offset part of that. Sales in Europe, the Middle East and Africa grew 12% to $239 million. Asia Pacific sales grew 3% to $208 million.

Adjusted pro forma operating EBITDA was $222 million, against $268 million a year earlier. On a GAAP basis, continuing operations lost $54 million. Corteva set its 2026 operating EBITDA outlook at $1.100 billion to $1.125 billion and operating EPS at $0.76 to $0.80. It expects $130 million to $140 million of restructuring charges this year for its crop protection network. The board also approved the first common dividend since the spin.

Seven Desks Weigh In on Corteva

Salvator Tiano of KeyBanc kept Overweight and lowered his target from $17 to $14 today. John Roberts of Mizuho lowered his target from $16 to $13 today. He had reiterated Outperform on November 12.

Five more calls came last week, after the report. Kristen Owen of Oppenheimer downgraded Corteva to Perform from Outperform. Patrick Cunningham of Citi kept Neutral and lowered his target from $13.65 to $10.30. Jeffrey Zekauskas of JPMorgan kept Overweight and lowered his target from $19 to $16. Joshua Spector of UBS kept Neutral and cut his target from $15 to $10. Arun Viswanathan of RBC kept Outperform and lowered his target from $17 to $11.

Corteva’s Record on AnaChart

Corteva draws 13 covering analysts on AnaChart. Ratings split 60% Buy and 40% Hold. Some targets on file, such as Argus’s $91 from September, predate the separation. AnaChart’s tracking shows 92.21% of Corteva targets get met. That takes about 338 days on average. Viswanathan’s met ratio is 26 of 30, and Zekauskas’s is 20 of 22.

Milestone Pharmaceuticals

Milestone Pharmaceuticals sells CARDAMYST, a nasal spray that patients use to stop episodes of paroxysmal supraventricular tachycardia, a sudden fast heartbeat. The company has offices in Montreal and Charlotte, North Carolina. It reported third-quarter results last week. Revenue came to $2.96 million, 146.7% above the $1.2 million consensus. Its loss was $0.18 a share, an 18.2% narrower loss than the $0.22 expected.

What Drove Milestone’s Quarter

License and other revenue made up $2.0 million of the total. CARDAMYST product revenue was $963,000, a 73% gain from the second quarter. About 3,400 prescriptions have been written since launch, by about 1,600 prescribers. Plans covering about two-thirds of commercially insured lives now cover the drug.

Milestone also announced cost cuts. It expects to cut operating expenses by about 30%, with the actions done by the first quarter of 2027. It cut its field sales force from about 60 to about 45 representatives in August and is moving that team in-house. Chief financial officer Amit Hasija and chief medical officer David Bharucha have left the leadership team.

The net loss was $25.8 million, against $11.9 million a year earlier. Cash and short-term investments stood at $145.4 million at the end of September. Milestone now says that runway lasts into late 2028. Topline data from its Phase 3 trial in atrial fibrillation with rapid ventricular rate is due in the second half of 2028. Chief executive Joseph Oliveto said, “We are encouraged by the early progress of CARDAMYST.”

Three Desks Cut Milestone

Brandon Folkes of H.C. Wainwright kept Buy and lowered his target from $8 to $6 today. Edward Tenthoff of Piper Sandler kept Overweight and lowered his target from $7 to $3. Ritu Baral of TD Cowen lowered her target to $5. AnaChart’s last record for her shows a Hold rating and an $8 target from December 2025.

Milestone’s Record on AnaChart

Before today’s moves, Milestone drew 4 covering analysts on AnaChart. Their average target was $7.67. Ratings split 75% Buy and 25% Hold. AnaChart’s tracking shows 17.58% of Milestone targets get met. Folkes has a met ratio of 0 of 5.

Ondas

Ondas builds drones, counter-drone systems and other autonomous systems for defense, security and industrial customers. The company is based in West Palm Beach, Florida. It reported third-quarter results on Thursday, November 12. Revenue came to $167.5 million, 12.9% above the $148.33 million consensus. Its loss was $0.10 a share, a 23.1% narrower loss than the $0.13 expected.

What Drove Ondas’s Quarter

Revenue was $10.1 million a year earlier and $83.8 million in the second quarter. Ondas has closed six acquisitions, including DZYNE Technologies and Cyberhawk. On a pro forma basis, organic growth was 64%. Bookings reached $214 million. That included $100 million at its Ondas Sentinel defense unit, of which $53.7 million was follow-on orders for ULTRA. Backlog ended the quarter at $835 million.

The gross margin was 21.8%, down from 43.1% in the second quarter. The net loss was $64.7 million, which includes $125.1 million of non-cash warrant gains. The adjusted EBITDA loss was $59.7 million. Ondas ended September with $820.3 million in cash, restricted cash and short-term investments.

Ondas’s New Outlook

Ondas now expects 2026 revenue of at least $550 million, up from $525 million to $550 million. It sees fourth-quarter revenue above $250 million and set an initial 2027 target of at least $1.1 billion. It moved its company-wide adjusted EBITDA breakeven target up to the third quarter of 2027, from the fourth. Chairman and chief executive Eric Brock said the quarter shows “the growing benefits of Ondas’ integrated operating platform.”

Four Desks Weigh In on Ondas

Jonathan Siegmann of Stifel kept Buy and lowered his target from $18 to $15 today. Three calls came last week, after the report. Max Michaelis of Lake Street kept Buy and lowered his target from $19 to $14. Austin Bohlig of Needham kept Buy and also lowered his target from $19 to $14. Trevor Walsh of Citizens reiterated Market Outperform and a $14 target.

Ondas’s Record on AnaChart

Ondas draws 6 covering analysts on AnaChart. Their average target is $18.83. Ratings split 96.77% Buy and 3.23% Hold. AnaChart’s tracking shows 51.85% of Ondas targets get met. That takes about 144 days on average. Michaelis has a met ratio of 5 of 10, and Bohlig 3 of 13.

What the Performance Matrix Shows

Corteva has the best met ratio of the three, and Milestone the lowest. A met Corteva target takes about 338 days. A met Ondas target lands in about 144. AnaChart’s first Milestone forecast dates to June 2019.

AnaChart tracks every price target against what happened to the stock afterward, desk by desk and analyst by analyst. The ticker pages linked above break out each record by analyst, firm and year. AnaChart’s full data set holds more than 760,000 analyst calls on more than 9,000 tickers, active and delisted. More than 680,000 carry a price target and more than 730,000 carry a rating. It is the second largest database of its kind. The raw file is available through the AnaChart store.

The previous update covered YETI, NeuroPace and Twist on November 13.

Top analyst price target moves on AnaChart, November 16 2026
Top analyst price target moves on AnaChart.com, November 16 2026